Search results
Results From The WOW.Com Content Network
When the antiviral medication Paxlovid was approved in 2021 to treat COVID-19, doctors began noticing a trend among some patients: a rebound case of the virus. After treatment, some people would ...
More specifically, Paxlovid rebound describes a case where the patient has had the full five-day course of treatment and then develops the return of symptoms or tests positive after having tested ...
A study published in June by researchers at the Mayo Clinic found that less than 1% of 483 high-risk patients who had received Paxlovid experienced rebound symptoms. Anecdotal reports suggest that ...
Both EPIC-HR and EPIC-SR were randomized controlled trials that provide information about COVID‑19 rebound. [14] Data from these trials showed that rebound in SARS-CoV-2 (RNA or virus) shedding or COVID‑19 symptoms occurred in a subset of participants and happened in both the participants receiving nirmatrelvir/ritonavir and the placebo. [14]
The symptoms of COVID rebound are often mild similar to a cold: Sore throat. Cough. Fatigue. Runny nose. Headache. Shortness of breath. Muscle aches. “In almost all cases the rebound event is ...
The Mayo Clinic released a study in June that reported that four people out of a group of 483 individuals who took Paxlovid developed COVID-19 rebound symptoms. It’s not clear why some people ...
But the rebound rate is comparable between people who took Paxlovid and those who didn’t. Rebound symptoms are also seen with other illnesses, like the flu, and they’re typically milder than ...
Health care providers stress that Paxlovid hasn’t necessarily failed people whose Covid-19 symptoms return following treatment; it still may have saved them from hospitalization and death.